Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Non-Deal Roadshow (May 2025)
22 slides from Island Pharmaceuticals's roadshow presentation, May 8, 2025
Slide 1: ASX Announcement: US non-deal roadshow presentation
8 May 2025 ASX Announcement US non-deal roadshow presentation MELBOURNE Australia, 6 May 2025: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to provide the attached copy of the Company’s latest investor presentation, which will
Slide 2: About Island Pharmaceuticals
Approved for release to the ASX by: David Foster (CEO and Managing Director) Island Pharmaceuticals Limited info@islandpharmaceuticals.com Investors and media, for further information, please contact: Henry Jordan Six Degrees Investor Relations +61 (0) 431 271 538 henry.jordan@sdir.com.au About Isla
Slide 3: Combatting Urgent Viral Disease Threats
For personal use only COMBATTING URGENT VIRAL DISEASE THREATS US NON-DEAL ROADSHOW PRESENTATION DR DAVID FOSTER, MANAGING DIRECTOR May 2025 (ASX: ILA) ISLAND PHARMACEUTICALS 1 February 2025
Slide 4: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (Company or Future performance Island Pharmaceuticals). This presentation contains certain "forward-looking statements". The words "expect", "anticipate", Not an offer or financia
Slide 5: For personal use only
For personal use only Dengue infects up Major market to 400m per year* potential Island Pharmaceuticals (ASX: ILA) is an antiviral therapeutics company Positive results in Phase 2a/b PROTECT clinical targeting infectious diseases aggressive models trial in dengue underway Priority Review Pipeline ex
Slide 6: Corporate Overview
CORPORATE OVERVIEW Snapshot Price & volume (12 month) For personal use only Share on issue1: 210,259,700 Price per share1: $0.18 Market capitalisation1: $37.85m Cash at bank (31 March 2025)2: $4.82m DoD grant funding to directly support USD $625k the Phase 2a/b PROTECT clinical study Substantial sha
Slide 7: Company Overview
COMPANY OVERVIEW For personal use only - Lead asset, ISLA-101 repurposed for dengue fever and other mosquito (or vector) borne diseases - ISLA-101 has been part of 40+ Phase I, II and III human clinical trials in indications including cancer and respiratory diseases, and deemed safe by regulators -
Slide 8: Benefits of Drug Repurposing
BENEFITS OF DRUG REPURPOSING For personal use only ILA is well advanced on its clinical development pipeline ISLAND PHARMACEUTICALS 6 MAY 2025
Slide 9: Increased Likelihood of Success
INCREASED LIKELIHOOD OF SUCCESS For personal use only Drug Development - Overall probability of success Hematology 17.8% • Treatments for infectious disease have a statistically higher likelihood of overall success in clinical trials Infectious Disease 15.5% Ophthalmology 13.9% • Anti-infective trea
Slide 10: Dengue – Infection Can Lead to Lethal Outcomes
DENGUE – INFECTION CAN LEAD TO LETHAL OUTCOMES For personal use only Uninfected mosquito • Dengue is a viral infection transmitted to humans through the bite of infected mosquitoes • It directly impacts white blood cell count and platelets - vital for body protective mechanisms 1-14 day • Moderate t
Slide 11: Dengue - Common and Spreading
DENGUE - COMMON AND SPREADING For personal use only US$8.9B Estimated impact to the HealthMap: recent reports of local or imported dengue cases (March 2025) economy from dengue fever “About half of the world's population is now at risk of dengue with an estimated 100 – 400 million infections occurri
Slide 12: Dengue by 2050 Is More Prevalent
DENGUE BY 2050 IS MORE PREVALENT For personal use only Driven by: Warmer temperatures • Accelerating development • Increases activity of female mosquitoes • Reduces incubation time for mosquito to become infectious • Allow mosquitoes to survive longer through winter High humidity • Improves mosquito
Slide 13: A Multi-Billion-Dollar Market Opportunity
A MULTI-BILLION-DOLLAR MARKET OPPORTUNITY For personal use only Dengue Fever treatment – Growth forecast (USD Bn) 4.00 $3.67 $3.47 • There is currently no specific treatment for dengue – 3.50 $3.29 providing ILA with the opportunity to be first to market $3.12 $2.96 • Takeda Pharmaceuticals project
Slide 14: ISLA-101 – Broad Activity Evident
ISLA-101 – BROAD ACTIVITY EVIDENT For personal use only Demonstrated activity against flaviviruses (subgroup of arboviruses) in models of infection • ISLA-101 has demonstrated broad anti-viral activity in in-vitro models • Demonstrated potent anti dengue-1 activity in in-vitro models using fresh Den
Slide 15: Preventing Animal Deaths from Lethal Dengue and Protective Against Zika
PREVENTING ANIMAL DEATHS FROM LETHAL DENGUE AND PROTECTIVE AGAINST ZIKA For personal use only Survival curve showing protection from lethal dengue change by Increasing dose of ISLA101 (mouse model). Fraser et al. J. Infect. Dis 2014 ISLAND PHARMACEUTICALS 13 MAY 2025
Slide 16: Phase 2a/b (PROTECT) Study Overview
PHASE 2A/B (PROTECT) STUDY OVERVIEW For personal use only Randomised, double blind, placebo-controlled dengue challenge study – prophylactic and treatment challenge: • Study include a prophylactic (Phase 2a) and therapeutic (Phase 2b) arm • Prophylactic Cohort- 2a: 4 subjects randomized 3:1 • Therap
Slide 17: Phase 2a/b (PROTECT) Design
PHASE 2A/B (PROTECT) DESIGN For personal use only Phase 2A: Prophylactic (preventative) cohort Administer ISLA-101 daily • Phase 1 (completed April 2024) achieved all study outcomes relating to safety and dosing, demonstrating benefit of Challenge study approach -3 0 (Infection) 20 28 45 90 • Phase
Slide 18: Clinical Trial and Regulatory Pathway
CLINICAL TRIAL AND REGULATORY PATHWAY For personal use only A defined clinical and regulatory route based on Phase 2a/b study results • Two likely pathways depending on Phase 2a/b results • Discussions advancing with multiple potential strategic partners for additional phase 2 and 3 clinical trials
Slide 19: Galidesivir WIP - Significant Pipeline Opportunity
GALIDESIVIR WIP - SIGNIFICANT PIPELINE OPPORTUNITY For personal use only Galidesivir – potential to tackle Ebola, Marburg, Zika & other RNA viruses - 12-month binding LOI signed in Sept 2024 - Small molecule, re-purposable with reduced timeframe to market - Substantial Phase 1 human safety data - De
Slide 20: Potential Regulatory Fast Track
POTENTIAL REGULATORY FAST TRACK For personal use only Existing Galidesivir data package and FDA Animal Rule unlock quicker approval path • Data package includes successful non-human primate study in Marburg and two phase 1 safety studies • FDA’s Animal Rule allows for approval of drugs for in indica
Slide 21: Near Term Milestones
NEAR TERM MILESTONES For personal use only A number of value catalysts pending in the coming months Milestone Timeframe Advancement of Galidesivir opportunity May 2025 High level, unblinded results from Phase 2a/b PROTECT study May 2025 Meeting with US FDA to discuss Phase 2a/b PROTECT study results
Slide 22: Island Pharmaceuticals
For personal use only Island Pharmaceuticals (ASX: ILA) islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals ISLAND PHARMACEUTICALS 20 MAY 2025
Island Pharmaceuticals — Non-Deal Roadshow (May 2025) on 6ix